公开(公告)号：US20210000810A1

公开(公告)日：2021-01-07

申请号：US16869450

申请日：2020-05-07

Applicant: NOVARTIS AG

Inventor： Tinya Abrams ,  Larry Alexander Gaither

IPC: A61K31/4439 ,  A61P35/00 ,  A61K31/381

Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.

公开(公告)号：US10786578B2

公开(公告)日：2020-09-29

申请号：US15329818

申请日：2015-07-27

Applicant: Novartis AG

Inventor： Tinya Abrams ,  Steven Bruce Cohen ,  Dylan Daniel ,  Catrin Finner ,  Bernhard Hubert Geierstanger ,  Thomas Huber ,  William Mallet ,  Matthew John Meyer ,  Weijia Ou ,  Siew Ho Schleyer ,  Kathrin Ulrike Tissot-Daguette

IPC: A61K39/00 ,  A61K47/68 ,  C07K16/28 ,  A61K51/10 ,  A61K49/00 ,  A61P35/02 ,  A61K39/395

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

公开(公告)号：US10695333B2

公开(公告)日：2020-06-30

申请号：US16204471

申请日：2018-11-29

Applicant: NOVARTIS AG

Inventor： Tinya Abrams ,  Larry Alexander Gaither

IPC: A61K31/4439 ,  A61P35/00 ,  A61K31/381 ,  C07D409/06

Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.

公开(公告)号：US11833215B2

公开(公告)日：2023-12-05

申请号：US16893359

申请日：2020-06-04

Applicant: Novartis AG

Inventor： Tinya Abrams ,  Steven Bruce Cohen ,  Dylan Daniel ,  Catrin Finner ,  Bernhard Hubert Geierstanger ,  Thomas Huber ,  William Mallet ,  Matthew John Meyer ,  Weijia Ou ,  Siew Ho Schleyer ,  Kathrin Ulrike Tissot-Daguette

IPC: C07K16/00 ,  A61K39/00 ,  A61K47/68 ,  C07K16/28 ,  A61K51/10 ,  A61K49/00 ,  A61P35/02 ,  A61K39/395

CPC classification number: A61K47/6803 ,  A61K39/39558 ,  A61K47/6849 ,  A61K49/00 ,  A61K51/103 ,  A61K51/1093 ,  A61P35/02 ,  C07K16/2803 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

公开(公告)号：US11179365B2

公开(公告)日：2021-11-23

申请号：US16190298

申请日：2018-11-14

Applicant: NOVARTIS AG

Inventor： Tinya Abrams ,  Larry Alexander Gaither

IPC: A61K31/381 ,  A61K31/519 ,  A61P35/00 ,  A61K9/00

Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.

公开(公告)号：US10117953B2

公开(公告)日：2018-11-06

申请号：US15284444

申请日：2016-10-03

Applicant: Novartis AG

Inventor： Tinya Abrams ,  Steven Bruce Cohen ,  Christie P. Fanton ,  Thomas Huber ,  Kathy Miller ,  Siew Ho Schleyer ,  Kathrin Ulrike Tissot-Daguette ,  Catrin Finner

IPC: A61K47/48 ,  A61K47/68 ,  A61K45/06 ,  C07K16/28 ,  A61K31/537 ,  A61K47/12 ,  A61K47/26 ,  A61K9/19 ,  A61K9/00 ,  A61K49/00 ,  A61K51/10 ,  C07K16/32 ,  A61K39/00

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.